Piper Sandler Maintains Overweight on Solid Biosciences, Raises Price Target to $18

Solid Biosciences Inc.

Solid Biosciences Inc.

SLDB

0.00

Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ: SLDB) with a Overweight and raises the price target from $17 to $18.